慢性自发性荨麻疹发病过程中肥大细胞作用及其靶向治疗进展

doi:10.35541/cjd.20240291

Abstract

Abstract: 【Abstract】 Chronic spontaneous urticaria （CSU） is a common skin disorder primarily driven by mast cells. It has been found that mast cells play a crucial role in the development of CSU mainly through type Ⅰ and Ⅱb autoimmune responses. This review summarizes the mechanisms of action of mast cells in CSU, new methods of targeting mast cells for the treatment of CSU, and future research directions, providing a reference for the clinical treatment of CSU.

Key words: Chronic urticaria, Mast cells, Autoimmunity, Antibodies, monoclonal, Therapies, investigational, Small molecule drug

Xu Zhuohong, Zhou Xuyue, Hu Yu, Gu Heng. Role of mast cells in the pathogenesis of chronic spontaneous urticaria and advances in mast cell-targeted therapies[J]. Chinese Journal of Dermatology,2024,e20240291. doi:10.35541/cjd.20240291

References ［42］

［1］	Kolkhir P, Church MK, Weller K, et al. Autoimmune chronic spontaneous urticaria: what we know and what we do not know［J］. J Allergy Clin Immunol, 2017,139（6）:1772⁃1781.e1. doi: 10.1016/j.jaci.2016.08.050.
［2］	Dobrican CT, Muntean IA, Pintea I, et al. Immunological signature of chronic spontaneous urticaria （review）［J］. Exp Ther Med, 2022,23（6）:381. doi: 10.3892/etm.2022.11309.
［3］	Nakano N, Kitaura J. Mucosal mast cells as key effector cells in food allergies［J］. Cells, 2022,11（3）:329. doi: 10.3390/cells 11030329.
［4］	Reber LL, Sibilano R, Mukai K, et al. Potential effector and immunoregulatory functions of mast cells in mucosal immunity［J］. Mucosal Immunol, 2015,8（3）:444⁃463. doi: 10.1038/mi. 2014.131.
［5］	Elieh⁃Ali⁃Komi D, Metz M, Kolkhir P, et al. Chronic urticaria and the pathogenic role of mast cells［J］. Allergol Int, 2023,72（3）:359⁃368. doi: 10.1016/j.alit.2023.05.003.
［6］	Schmetzer O, Lakin E, Topal FA, et al. IL⁃24 is a common and specific autoantigen of IgE in patients with chronic spontaneous urticaria［J］. J Allergy Clin Immunol, 2018,142（3）:876⁃882. doi: 10.1016/j.jaci.2017.10.035.
［7］	Kolkhir P, Muñoz M, Asero R, et al. Autoimmune chronic spontaneous urticaria［J］. J Allergy Clin Immunol, 2022,149（6）:1819⁃1831. doi: 10.1016/j.jaci.2022.04.010.
［8］	Nagata Y, Suzuki R. FcεRI: a master regulator of mast cell functions［J］. Cells, 2022,11（4）:622. doi: 10.3390/cells1104 0622.
［9］	Kaplan A, Lebwohl M, Giménez⁃Arnau AM, et al. Chronic spontaneous urticaria: focus on pathophysiology to unlock treatment advances［J］. Allergy, 2023,78（2）:389⁃401. doi: 10. 1111/all.15603.
［10］	Hide M, Francis DM, Grattan CE, et al. Autoantibodies against the high⁃affinity IgE receptor as a cause of histamine release in chronic urticaria［J］. N Engl J Med, 1993,328（22）:1599⁃1604. doi: 10.1056/NEJM199306033282204.
［11］	Asero R, Marzano AV, Ferrucci S, et al. Co⁃occurrence of IgE and IgG autoantibodies in patients with chronic spontaneous urticaria［J］. Clin Exp Immunol, 2020,200（3）:242⁃249. doi: 10. 1111/cei.13428.
［12］	中华医学会皮肤性病学分会荨麻疹研究中心. 中国荨麻疹诊疗指南（2022版）［J］. 中华皮肤科杂志, 2022,55（12）:1041⁃1049. doi: 10.35541/cjd.20220609.
［13］	Maurer M, Rosén K, Hsieh HJ, et al. Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria［J］. N Engl J Med, 2013,368（10）:924⁃935. doi: 10.1056/NEJMoa 1215372.
［14］	Thomas D, McDonald VM, Stevens S, et al. Biologics （mepolizumab and omalizumab） induced remission in severe asthma patients［J］. Allergy, 2024,79（2）:384⁃392. doi: 10.1111/all.15867.
［15］	Yuan W, Hu S, Li M, et al. Efficacy and safety of omalizumab in Chinese patients with anti⁃histamine refractory chronic spontaneous urticaria［J］. Dermatol Ther, 2022,35（4）:e15303. doi: 10.1111/dth.15303.
［16］	Gasser P, Tarchevskaya SS, Guntern P, et al. The mechanistic and functional profile of the therapeutic anti⁃IgE antibody ligelizumab differs from omalizumab［J］. Nat Commun, 2020,11（1）:165. doi: 10.1038/s41467⁃019⁃13815⁃w.
［17］	Maurer M, Giménez⁃Arnau AM, Sussman G, et al. Ligelizumab for chronic spontaneous urticaria［J］. N Engl J Med, 2019,381（14）:1321⁃1332. doi: 10.1056/NEJMoa1900408.
［18］	Kuo BS, Li CH, Chen JB, et al. IgE⁃neutralizing UB⁃221 mAb, distinct from omalizumab and ligelizumab, exhibits CD23⁃mediated IgE downregulation and relieves urticaria symptoms［J］. J Clin Invest, 2022,132（15）:e157765. doi: 10.1172/JCI 157765.
［19］	Johal KJ, Saini SS. Current and emerging treatments for chronic spontaneous urticaria［J］. Ann Allergy Asthma Immunol, 2020,125（4）:380⁃387. doi: 10.1016/j.anai.2019.08.465.
［20］	Ramirez Molina C, Falkencrone S, Skov PS, et al. GSK2646264, a spleen tyrosine kinase inhibitor, attenuates the release of histamine in ex vivo human skin［J］. Br J Pharmacol, 2019,176（8）:1135⁃1142. doi: 10.1111/bph.14610.
［21］	Metz M, Sussman G, Gagnon R, et al. Fenebrutinib in H1 antihistamine⁃refractory chronic spontaneous urticaria: a randomized phase 2 trial［J］. Nat Med, 2021,27（11）:1961⁃1969. doi: 10.1038/s41591⁃021⁃01537⁃w.
［22］	Maurer M, Berger W, Giménez⁃Arnau A, et al. Remibrutinib, a novel BTK inhibitor, demonstrates promising efficacy and safety in chronic spontaneous urticaria［J］. J Allergy Clin Immunol, 2022,150（6）:1498⁃1506.e2. doi: 10.1016/j.jaci.2022.08.027.
［23］	Jain V, Giménez⁃Arnau A, Hayama K, et al. Remibrutinib demonstrates favorable safety profile and sustained efficacy in chronic spontaneous urticaria over 52 weeks［J］. J Allergy Clin Immunol, 2024,153（2）:479⁃486.e4. doi: 10.1016/j.jaci.2023. 10.007.
［24］	Morales JK, Falanga YT, Depcrynski A, et al. Mast cell homeostasis and the JAK⁃STAT pathway［J］. Genes Immun, 2010,11（8）:599⁃608. doi: 10.1038/gene.2010.35.
［25］	Clauzure M, Táquez Delgado MA, Phillip JM, et al. Histamine H4 receptor agonism induces antitumor effects in human T⁃cell lymphoma［J］. Int J Mol Sci, 2022,23（3）:1378. doi: 10.3390/ijms23031378.
［26］	Murata Y, Song M, Kikuchi H, et al. Phase 2a, randomized, double⁃blind, placebo⁃controlled, multicenter, parallel⁃group study of a H4 R⁃antagonist （JNJ⁃39758979） in Japanese adults with moderate atopic dermatitis［J］. J Dermatol, 2015,42（2）:129⁃139. doi: 10.1111/1346⁃8138.12726.
［27］	Kollmeier AP, Barnathan ES, O'Brien C, et al. A phase 2a study of toreforant, a histamine H4 receptor antagonist, in eosinophilic asthma［J］. Ann Allergy Asthma Immunol, 2018,121（5）:568⁃574. doi: 10.1016/j.anai.2018.08.001.
［28］	Werfel T, Layton G, Yeadon M, et al. Efficacy and safety of the histamine H4 receptor antagonist ZPL⁃3893787 in patients with atopic dermatitis［J］. J Allergy Clin Immunol, 2019,143（5）:1830⁃1837.e4. doi: 10.1016/j.jaci.2018.07.047.
［29］	Oliver ET, Chichester K, Devine K, et al. Effects of an oral CRTh2 antagonist （AZD1981） on eosinophil activity and symptoms in chronic spontaneous urticaria［J］. Int Arch Allergy Immunol, 2019,179（1）:21⁃30. doi: 10.1159/000496162.
［30］	Brightling CE, Gaga M, Inoue H, et al. Effectiveness of fevipiprant in reducing exacerbations in patients with severe asthma （LUSTER⁃1 and LUSTER⁃2）: two phase 3 randomised controlled trials［J］. Lancet Respir Med, 2021,9（1）:43⁃56. doi: 10.1016/S2213⁃2600（20）30412⁃4.
［31］	Lee JK, Simpson RS. Dupilumab as a novel therapy for difficult to treat chronic spontaneous urticaria［J］. J Allergy Clin Immunol Pract, 2019,7（5）:1659⁃1661.e1. doi: 10.1016/j.jaip. 2018.11.018.
［32］	Abadeh A, Lee JK. Long⁃term follow⁃up of patients treated with dupilumab for chronic spontaneous urticaria: a case report［J］. SAGE Open Med Case Rep, 2022,10:2050313X221117702. doi: 10.1177/2050313X221117702.
［33］	Maurer M, Casale TB, Saini SS, et al. Dupilumab in patients with chronic spontaneous urticaria （LIBERTY⁃CSU CUPID）: two randomized, double⁃blind, placebo⁃controlled, phase 3 trials［J］. J Allergy Clin Immunol, 2024,154（1）:184⁃194. doi: 10.1016/j.jaci.2024.01.028.
［34］	Bernstein JA, Singh U, Rao MB, et al. Benralizumab for chronic spontaneous urticaria［J］. N Engl J Med, 2020,383（14）:1389⁃1391. doi: 10.1056/NEJMc2016395.
［35］	Sabag DA, Matanes L, Bejar J, et al. Interleukin⁃17 is a potential player and treatment target in severe chronic spontaneous urticaria［J］. Clin Exp Allergy, 2020,50（7）:799⁃804. doi: 10. 1111/cea.13616.
［36］	Sofen H, Bissonnette R, Yosipovitch G, et al. Efficacy and safety of vixarelimab, a human monoclonal oncostatin M receptor β antibody, in moderate⁃to⁃severe prurigo nodularis: a randomised, double⁃blind, placebo⁃controlled, phase 2a study［J］. EClinicalMedicine, 2023,57:101826. doi: 10.1016/j.eclinm.2023. 101826.
［37］	Menzies⁃Gow A, Corren J, Bourdin A, et al. Tezepelumab in adults and adolescents with severe, uncontrolled asthma［J］. N Engl J Med, 2021,384（19）:1800⁃1809. doi: 10.1056/NEJMoa 2034975.
［38］	Alvarado D, Maurer M, Gedrich R, et al. Anti⁃KIT monoclonal antibody CDX⁃0159 induces profound and durable mast cell suppression in a healthy volunteer study［J］. Allergy, 2022,77（8）:2393⁃2403. doi: 10.1111/all.15262.
［39］	Wedi B. Inhibition of KIT for chronic urticaria: a status update on drugs in early clinical development［J］. Expert Opin Investig Drugs, 2023,32（11）:1043⁃1054. doi: 10.1080/13543784.2023. 2277385.
［40］	Karra L, Berent⁃Maoz B, Ben⁃Zimra M, et al. Are we ready to downregulate mast cells?［J］. Curr Opin Immunol, 2009,21（6）:708⁃714. doi: 10.1016/j.coi.2009.09.010.
［41］	Altrichter S, Staubach P, Pasha M, et al. An open⁃label, proof⁃of⁃concept study of lirentelimab for antihistamine⁃resistant chronic spontaneous and inducible urticaria［J］. J Allergy Clin Immunol, 2022,149（5）:1683⁃1690.e7. doi: 10.1016/j.jaci.2021.12.772.
［42］	Metz M, Kolkhir P, Altrichter S, et al. Mast cell silencing: a novel therapeutic approach for urticaria and other mast cell⁃mediated diseases［J］. Allergy, 2024,79（1）:37⁃51. doi: 10.1111/all.15850.

[1]	Yue Shuzhen, Shu Ye, Luo Yangyang, Li Keyao, Zhang Yuanyuan, Tang Jianping, Wei Zhu. Efficacy and safety of omalizumab in the treatment of chronic urticaria in children: a retrospective study [J]. Chinese Journal of Dermatology, 2024, 57(4): 354-358.
[2]	Zhou Tiantian, Wu Xuege, Yang Huan, Fang Xiao, Jiang Jinqiu, Chen Jingsi, Luo Xiaoyan, Wang Hua. Analysis of the etiology and factors associated with the severity of chronic spontaneous urticaria in children [J]. Chinese Journal of Dermatology, 2024, 57(4): 324-330.
[3]	Zhang Yude, Wang Hongjuan, Kang Xiaojing. Stem cell therapy for vitiligo: advances in basic and clinical research [J]. Chinese Journal of Dermatology, 2024, 0(3): 20240127-e20240127.
[4]	He Xingyan, Zhang Kejia, Feng Yanyan. Noval G protein-coupled receptor X2 in dermatology [J]. Chinese Journal of Dermatology, 2024, 0(3): 20240124-e20240124.
[5]	Gao Jinping, Zhang Xuejun, . Clinical application of baricitinib in dermatology [J]. Chinese Journal of Dermatology, 2024, 0(3): 20230528-e20230528.
[6]	Yao Manxue, Zhou Naihui. Stevens-Johnson syndrome/toxic epidermal necrolysis associated with programmed death-1/programmed death-ligand 1 inhibitors [J]. Chinese Journal of Dermatology, 2024, 0(3): 20220644-e20220644.
[7]	Zhao Miaomiao, Yu Peiyao, Yang Haiqian, Yu Yingyao, Ma Li, Mou Wenjia, Shang Yuanyuan. Efficacy, safety, and factors influencing efficacy of omalizumab in the treatment of chronic spontaneous urticaria: a prospective, single-center study [J]. Chinese Journal of Dermatology, 2024, 57(12): 1091-1098.
[8]	Wang Haoyang, Wang Yidan, Lu Yan . Role of neurogenic inflammatory factors in the pathogenesis of vitiligo [J]. Chinese Journal of Dermatology, 2024, 57(1): 78-81.
[9]	Liang Yunsheng, Li Zhanhong, Wu Yibei. Progress in the treatment of chronic spontaneous urticaria: insights from the changes in the understanding of its pathogenesis [J]. Chinese Journal of Dermatology, 2023, 56(6): 552-558.
[10]	Yang Nali, Xu Qiuyang, Wu Hanwen, Ye Yahui, Zhu Jiling, Liu Jingjing, Li Zhiming. Efficacy and safety of omalizumab in the treatment of chronic urticaria: a retrospective analysis [J]. Chinese Journal of Dermatology, 2023, 56(6): 518-524.
[11]	Yang Lei, Zheng Gaofeng, Chu Lei, Ran Yuping. Mas-related G protein-coupled rceptor X2 in itch in atopic dermatitis [J]. Chinese Journal of Dermatology, 2023, 0(2): 20230078-e0230078.
[12]	Sun Xiaoli, Li Linfeng. Role of mast cells in the pathogenesis of allergic contact dermatitis [J]. Chinese Journal of Dermatology, 2022, 55(5): 449-451.
[13]	Zhao Zuotao. Diagnosis and treatment of chronic urticaria: current status and future prospects [J]. Chinese Journal of Dermatology, 2021, 54(12): 1105-1109.
[14]	Centre for Urticaria Research, Chinese Society of Dermatology. Consensus on management of chronic urticaria using anti-immunoglobulin E therapy （omalizumab） [J]. Chinese Journal of Dermatology, 2021, 54(12): 1057-1062.
[15]	Li Chunying, Li Shuli. Pathogenesis of vitiligo [J]. Chinese Journal of Dermatology, 2019, 52(9): 593-597.

Role of mast cells in the pathogenesis of chronic spontaneous urticaria and advances in mast cell-targeted therapies

PDF

PDF (Mobile)

Knowledge

Abstract

Cite this article

share this article

References ［42］

Related Articles 15

Metrics

Comments

Recommended 10